ZG-033

Evaluate the safety and tolerability of ZG033 injection in patients with advanced relapsed, metastatic, and refractory solid tumors and non-Hodgkin's lymphoma; Evaluate the pharmacokinetic (PK) parameters of single and multiple intravenous infusions of ZG033 injection; Evaluate the immunogenicity of intravenous infusion of ZG033 injection; Preliminary understanding of the activity of ZG033 injection in immunotherapy for advanced relapsed, metastatic, and refractory solid tumors and non-Hodgkin's lymphoma (ORR, DoR, DCR, PFS and other efficacy indicators);